Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2014 / Cilt: 24 - Sayı: 3

KAPPA LIGHT CHAIN MYELOMA

KAPPA HAFİF ZİNCİR MİYELOMU

Pages
203–205
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In our case, a rare kappa light chain myeloma and immunofixation electrophoresis has been referred to the importance of the diagnosis

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Multiple myeloma (MM) is a progressive and fatal desaese arising by neoplastic proliferation of plasma cells in the clinic mainly common skeletal lesions, anemia, against extremist tendencies, hypercalcemi, renal function impairment.
📊
Key Findings & Data:In the presence of overt clinical signs (eg, sedimentation rate, hypercalcemia, anemia, lytic bone lesions, such as hypergammaglobulinemia) although it can be placed easily recognize further investigations are required in atypical cases.
💡
Conclusion & Impact:In our case, a rare kappa light chain myeloma and immunofixation electrophoresis has been referred to the importance of the diagnosis
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Multiple myeloma (MM) is a progressive and fatal desaese arising by neoplastic proliferation of plasma cells in the clinic mainly common skeletal lesions, anemia, against extremist tendencies, hypercalcemi, renal function impairment. In the presence of overt clinical signs (eg, sedimentation rate, hypercalcemia, anemia, lytic bone lesions, such as hypergammaglobulinemia) although it can be placed easily recognize further investigations are required in atypical cases. As with the light chain myeloma cases which could not be detected in serum protein electrophoresis is readily determined by immunofixation electrophoresis. In our case, a rare kappa light chain myeloma and immunofixation electrophoresis has been referred to the importance of the diagnosis

Özet

Multiple miyelom (MM) plazma hücrelerinin neoplastik proliferasyonu sonucu ortaya çıkan, klinikte başlıca yaygın iskelet lezyonları, anemi, infeksiyonlara karşı aşırı eğilim, hiperkalsemi, böbrek fonksiyon bozukluğu ile kendini gösteren progresif ve fatal bir hastalıktır. Aşikar klinik bulgular varlığında (örn; sedimentasyon artışı, hiperkalsemi, anemi, litik kemik lezyonları, hipergamaglobulinemi gibi) tanı rahatlıkla konabilmesine karşın atipik olgularda ileri incelemeler gereklidir. Hafif zincir miyelom da olduğu gibi serum protein elektroforezinde tespit edilemeyen olgular imünfiksasyon elektroforezi ile kolaylıkla saptanabilir. Olgumuzda nadir görülen kappa hafif zincir miyelomuna ve imünfiksasyon elektroforezinin tanı konulmasındaki önemine değinilmiştir

🔖

Cite This Article

ATASOY, İ., KILIÇASLAN, B. (2014). KAPPA LIGHT CHAIN MYELOMA. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 24 - Sayı: 3, 203–205. https://ajindex.com/articles/214949

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Camp NJ, Werner TL, Cannon-Albright LA. Familial myeloma. The New England Journal of Medicine. 2008; 359(16):1734–5. [PubMed]
  2. Kasper DL, Braunwald E, Fauci AS, et al. Harison's Principles of Internal Medicine 16th. Edition. In: Anderson KC, Longo DC, editors. Plasma Cell Disorders. 2000: 205: 656-60
  3. The monoclonal gammopathies and plasma cell dyscrasias, Myeloma. In Williams Manual of Hematology. Lichtman MA, Beutler E, Kipps TJ, Williams WJ (eds)., McGraw Hill, 2003:361-75
  4. BCSH and UKMF Guidelines on the Management and Diagnosis of Multiple Myeloma Sept. 2010 14/10/2010
  5. Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology. 2004; 231: 11-23
  6. Kyle RA, Child JA, Durie BGM et al. Criteria for the clasification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57
  7. Drayson MT, Tang LX, Drwe R et al. Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900-2
  8. Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol 2013; 8:2007.